Integragen
ALINT
Company Profile
Business description
Integragen is engaged in the development of genetic biomarkers. It offers genomic and bioinformatic services, including clinical research, basic and human genetic research, bioinformatics and bioanalysis, agrigenomics, and genomics news, as well as genomic research tools and solutions to microbiologic researchers.
Contact
Genopole Campus 1 - Genavenir
85 rue Henri Desbrueres
Evry91000
FRAT: +33 160910900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
39
Stocks News & Analysis
stocks
Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?
From AI integration to capital expenditure increases, here’s what we expect in Alphabet’s earnings report.
stocks
ASX energy share remains cheap despite strong outlook
Santos reports a solid quarter on the back of higher commodity prices - yet the shares look undervalued.
stocks
Moated AI-proof tech play hiding in the ASX 100
ChatGPT and large language models should be a tailwind for this company.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,990.80 | 20.60 | 0.23% |
| CAC 40 | 8,160.83 | 3.01 | 0.04% |
| DAX 40 | 24,189.00 | 60.02 | 0.25% |
| Dow JONES (US) | 49,230.71 | 79.61 | -0.16% |
| FTSE 100 | 10,343.14 | 35.94 | -0.35% |
| HKSE | 25,925.65 | 52.42 | -0.20% |
| NASDAQ | 24,836.60 | 398.10 | 1.63% |
| Nikkei 225 | 60,537.36 | 821.18 | 1.38% |
| NZX 50 Index | 12,874.94 | 9.99 | -0.08% |
| S&P 500 | 7,165.08 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,766.40 | 17.20 | 0.20% |
| SSE Composite Index | 4,086.34 | 6.44 | 0.16% |